Duligotuzumab

From WikiMD's WELLNESSPEDIA

(Redirected from Duligotumab)

Duligotuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Merck KGaA and ImClone Systems.

Mechanism of Action[edit]

Duligotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). By binding to these receptors, duligotuzumab inhibits the growth and proliferation of cancer cells that overexpress these receptors.

Clinical Trials[edit]

Duligotuzumab has been studied in clinical trials for the treatment of various types of cancer, including head and neck cancer, colorectal cancer, and non-small cell lung cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.

Side Effects[edit]

Like all drugs, duligotuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, diarrhea, and skin rash. In some cases, these side effects can be severe and may require medical attention.

See Also[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Duligotuzumab&oldid=6528089"